Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

NIH starts evaluating second COVID-19 booster shots in adults

By Chris Newmarker | April 4, 2022

coronavirus COVID-19 Pfizer

[Photo by Fusion Medical Animation on Unsplash]

The NIH recently announced that it has started enrolling adults for a Phase 2 clinical trial evaluating various additional COVID-19 booster shots.

NIH’s National Institute of Allergy and Infectious Diseases (NIAID) is sponsoring the COVID-19 Variant Immunologic Landscape (COVAIL) trial.

“We are looking beyond the Omicron variant to determine the best strategy to protect against future variants,” NIAID Director Dr. Anthony S. Fauci said in a March 31 news release. “This trial will help us understand if we can use prototype and variant vaccines alone or together to shift immune responses to cover existing and emerging COVID-19 variants.”

The COVAIL trial will study immune responses induced by prototype vaccines and variant vaccine candidates — including bivalent vaccines, which target two SARS-CoV-2 variants. The goal is to inform future booster shot recommendations.

Moderna is manufacturing the study vaccines that will be administered. The researchers, led by Dr. Nadine Rouphael of the Hope Clinic at the Emory Vaccine Center in Atlanta, and Dr. Angela Branche of the University of Rochester Medical Center in New York, plan to have initial findings from the 24-clinic, 600-participant study ready by August 2022.

FDA last month authorized a second booster dose of COVID-19 vaccine for individuals who are immunocompromised or 50 and over. The expanded EUA covers vaccines from Pfizer/BioNTech and Moderna.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Emergent Biosolutions
Emergent hid quality problems from FDA, House report concludes
World Changing Ideas
Fast Company 2022 World-Changing Ideas Awards highlight multiple pharma innovations
Pfizer logo
Pfizer ticks up on Street-beating Q1, lessens full-year guidance
Pfizer logo
Pfizer’s COVID-19 antiviral disappoints as post-exposure prophylactic 

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards